Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEGAR T cells in GPC3-positive liver cancer
NCT04093648Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2020
- Primary completion
- Feb 2023
01
Overview
Phase 1, open-label, single-arm trial of TEGAR T cells in hepatocellular carcinoma (HCC) and hepatoblastoma, sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity Rate at 4 weeks. Planned start Jan 2020; status: withdrawn.
02
Drugs
TEGAR T cells
03
Conditions
hepatocellular carcinoma (HCC)hepatoblastoma
Beyond the preview
Go deeper on NCT04093648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093648.